HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
View All | Scroll Down Scroll Up
Quote:
Login Free Membership
Search:

Bear of the Day

Genomic Health, Inc. (GHDX)

Share
By: Zacks Equity Research
October 30, 2009 | Comment(s): 0
Recommended this article (0)
GHDX

Genomic Health Inc.'s (GHDX - Analyst Report) lead product is Oncotype DX, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence.

Even though sales of Oncotype remain robust and the company remains optimistic about its prospects, we are highly concerned about the company's reliance on the product for growth. We believe that Genomic needs to expand its product portfolio in order to sustain growth.

Furthermore, we are also concerned about the company's weak pipeline. These concerns have caused us to downgrade the stock to Underperform.

Genomic Health, Inc. (GHDX) : FULL ANALYST REPORT

Bear of the Day
Every day we feature one stock with a Zacks Recommendation of Sell that is set to underperform over the next 6+ months. We also provide you with free access to the in-depth research report on the stock. If you would like to see all our Buy and Sell rated stocks and in-depth research reports, then check out  Zacks Premium.

Read the full analyst report on GHDX

 

Please login to Zacks.com or register to post a comment.

Email
Print
Share
Rate Pos
Rate Neg
Attn. Zacks.com Visitors
Sell These Stocks Today
Make sure no Zacks #5 Rank "Strong Sell" stocks are lurking in your portfolio. They tend to perform only 1/6th as well as the market!
Get your free Welcome Gifts today*:
 1.  Zacks "Strong Sell" list.
 2.  Our e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary May 22, 2012 22:57 pm ET
DJIA 12502.81  -1.67 -0.01%
NASD 2839.08  -8.13 -0.29%
S&P 500 1316.63  0.64 0.05%
Partner Center

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Premium Screens
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Alert
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
People & Picks
Zacks Premium
Zacks Ultimate
Zacks.com: About Zacks | Education | Advertise | Affiliate | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2011 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.